Key result
Volumetric oil deposition on CT 1 day after transarterial chemoembolization correlated with predicted residual tumor enhancement on MRI at 1 month (r = 0.72, P < 0.001).
Why the study?
To evaluate whether early tumor response to TACE can be predicted by volumetric oil deposition on posttreatment CT in patients with leiomyosarcoma liver metastases.
Can volumetric oil deposition on posttreatment CT predict early tumor response on MRI in patients with leiomyosarcoma liver metastases treated with TACE?
Observational (n=32)
Can volumetric oil deposition on posttreatment CT predict early tumor response on MRI in patients with leiomyosarcoma liver metastases treated with TACE?
Volumetric oil deposition on CT 1 day after TACE can predict residual tumor enhancement on MRI at 1 month in leiomyosarcoma liver metastases.
May support early CT prediction of MRI response after TACE in leiomyosarcoma metastases; leaves open prospective validation before practice change.
OBJECTIVE: To predict early tumor response to transarterial chemoembolization (TACE) based on volumetric oil deposition on posttreatment computed tomography (CT) in patients with leiomyosarcoma liver metastases. METHODS: This retrospective lesion-by-lesion based study included 32 lesions. The volumetric percent enhancing tumor on pre-TACE and 1-month post-TACE venous phase magnetic resonance imaging (MRI), and the percent oil deposition on CT 1 day after TACE were calculated. The predicted post-TACE enhanced percentage was computed by subtracting percent oil deposition from baseline percent enhanced. RESULTS: Mean percentage of viable tumor on pre-TACE MRI was 90.6% ± 9.3%. Mean oil deposition was calculated as 51.4% ± 26.2%. Mean percentage of measured residual tumor enhancement 1 month after TACE was 58.3% ± 27%, which correlates with predicted enhancement percentage of 43.9% ± 25.1% (r = 0.72, P < 0.001). A threshold of 35.5% for enhancement reduction was determined to predict tumor response with an accuracy of 78.1%. CONCLUSION: Volumetric oil deposition on CT can predict residual enhancement on post-TACE MRI.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an observational in Leiomyosarcoma liver metastases (n=32). Volumetric oil deposition on posttreatment CT was evaluated on Residual tumor enhancement 1 month after TACE (r = 0.72, p=< 0.001). Volumetric oil deposition on CT 1 day after transarterial chemoembolization correlated with predicted residual tumor enhancement on MRI at 1 month (r = 0.72, P < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: